SG/CALL/MODERNA/160/0.1/21.06.24 | Delayed Deutsche Boerse AG 12:03:49 2024-05-13 pm EDT | ||
| 0.074 EUR | +57.45% |
|
| Current month | -37.33% | ||
| 1 month | -46.59% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-13 | 0.074 | +57.45% | 0 |
| 24-05-10 | 0.047 | -38.16% | 0 |
| 24-05-09 | 0.076 | +22.58% | 0 |
| 24-05-08 | 0.062 | +6.90% | 0 |
| 24-05-07 | 0.058 | -15.94% | 0 |
Delayed Quote Deutsche Boerse AG
Last update May 13, 2024 at 12:03 pm EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | 
Société Générale
|
| WKN | SQ4FQM |
| ISIN | DE000SQ4FQM1 |
| Date issued | 2022-11-16 |
| Strike | 160 $ |
| Maturity | 2024-06-21 (39 Days) |
| Parity | 10 : 1 |
| Emission price | 6.92 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 9.19 € |
|---|---|
| Lowest since issue | 0.04 € |
| Spread | 0.01 € |
| Spread % | 12.05% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
117.3
USD
Average target price
139.4
USD
Spread / Average Target
+18.79%
- Stock Market
- Warrants
- Warrant